No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.
COVID-19
SARS coronavirus 2 antibody titer
SARS-CoV-2
intravenous immunoglobulin
neutralizing antibodies
plasma
primary immunodeficiency
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
13 Nov 2020
13 Nov 2020
Historique:
received:
31
07
2020
accepted:
16
09
2020
pubmed:
18
9
2020
medline:
22
12
2020
entrez:
17
9
2020
Statut:
ppublish
Résumé
The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is particularly relevant for people with immune deficiencies, as their health depends on treatment with immunoglobulin preparations that need to contain neutralizing antibodies against the pathogens in their environment. Testing 54 intravenous immunoglobulin preparations, produced from plasma collected in Europe and the United States, confirmed highly potent neutralization of a seasonal coronavirus; however, no cross-neutralization of the new SARS-CoV-2 was seen.
Identifiants
pubmed: 32941626
pii: 5907985
doi: 10.1093/infdis/jiaa593
pmc: PMC7546122
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1960-1964Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Clin Virol. 2018 Apr;101:52-56
pubmed: 29427907
Vaccine. 2019 May 27;37(24):3151-3153
pubmed: 31060953
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Transfusion. 2021 Jan;61(1):12-16
pubmed: 32978802
J Infect. 2013 Aug;67(2):130-40
pubmed: 23583636
Semin Respir Crit Care Med. 2016 Aug;37(4):555-71
pubmed: 27486736
Emerg Infect Dis. 2009 Oct;15(10):1668-70
pubmed: 19861071
J Clin Virol. 2020 Aug;129:104540
pubmed: 32652475
J Med Virol. 2020 May;92(5):512-517
pubmed: 32073157
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Infect Dis. 2020 Jun 16;222(1):17-25
pubmed: 32296837
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Emerg Microbes Infect. 2020 Dec;9(1):900-902
pubmed: 32380903
Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8
pubmed: 16723558
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876